Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FOUND: Atai life sciences - What They Never Told You

North Carolina Wants to ‘Lead the Nation’ in Psychedelics. Here’s 1 ‘Strong Buy’ Stock to Buy Now.

As policy meets potential in North Carolina, Atai Life Sciences could be a solid portfolio addition now.

Barchart

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

Benzinga

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.

Benzinga

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.

Benzinga

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart

Read news from The Economist, FT, and more,
with one subscription

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Fortune

Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01

Benzinga

Psychedelic Stock Gainers And Losers From June 22, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Benzinga

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72

Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36

Benzinga

ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022

In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.

Benzinga

Christian Angermayer Bullish On Psychedelic Sector And Life Extension Technology

In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.

Benzinga

Psychedelics Atai Life Sciences: Optimizing Drug Development By Avoiding Big Pharma's Past Missteps

In the early days of the psychedelics industry, financial reports mean very little. Unless a company wildly misses its operating spending budget and hemorrhages cash by more than expected, the report is basically a synopsis of a given company’s highlights and milestones over the previous quarter.

Benzinga

Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development

Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Field Trip Health, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 20.93% at $0.94

Benzinga

Psychedelic Stock Gainers And Losers From May 9, 2022

GAINERS: LOSERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed down 13.47% at $3.34

Benzinga

Allied, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Allied (OTC:ALID) shares closed up 5.27% at $0.76

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97

Benzinga

Psychedelic Stock Gainers And Losers From April 14, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32

Benzinga

Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company

Christian Angermayer, founder and chairman of Atai Life Sciences (NASDAQ:ATAI), told Twitter that he bought 1 million shares of his company. “Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) the fact…

Benzinga

ATAI Life Sciences's Return On Capital Employed Insights

ATAI Life Sciences (NASDAQ:ATAI) brought in sales totaling $230.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 194.78%, resulting in a loss of $93.27 million.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.